Menu Close

Trending

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA
13th World Multispecifics Summit
4th Extracellular Vesicle-Based Therapeutic Development Summit
Mirati heads for FDA verdict on KRAS drug with new data
Roche trumpets new glofitamab data in lymphoma at ASCO

Tremfya

J&J

News/ News/ Sales and Marketing

J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay

, , , , , , 0 Comment

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23

X
J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay
https://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/

Login

CONTINUE TO SITE >
X
Close in 10 seconds